News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Analysis of post-hoc of CAIRO5
Photo taken from researchgate.net
Jun 26, 2024, 14:17

Analysis of post-hoc of CAIRO5

Arndt Vogel shared on X:

“Prognostic value of total tumor volume in CRC liver metastases. post-hoc of CAIRO5 Tumor total volume, but not RECIST 1.1 is prognostic for survival outcomes
5-yr Os 72% for TTV of 3 mL vs 7% for TTV of 300 mL”

Analysis of post-hoc of CAIRO5

Read further.
Source: Arndt Vogel/X

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.

Anne-Joëlle JJ Bakker Arjen M Rijken Arndt Vogel cancer Cornelis JA Punt Cornelis Verhoef Dirk J Grunhagen Geert Kazemier Gijs A Patijn I Quintus Molenaar Inez M Verpalen Irene MGC Nota J Michiel Zeeuw Jaap Stoker Jan Hein TM van Waesberghe Janneke E van den Bergh Johannes HW de Wilt John J Hermans Joost Huiskens Joost M Klaase Joran Roor Kelly R Voigt Koert P de Jong Krijn P van Lienden liver metastases Mahsoem Ali Marc RW Engelbrecht Marinde JG Bond Martijn PA Starmans Martinus J van Amerongen Michael F Gerhards Mike SL Liem Niels FM Kok Nina J Wesdorp OncoDaily Oncology Ronald M van Dam Ruby Kemna Rutger-Jan Swijnenburg Shira I Moos survival outcomes Susan van Dieren Theo M Ruers Thiery Chapelle Thomas M van Gulik Wouter KG Leclercq
Special Coverage
Insight
Nov 22, 2024, 10:13
Raymond Chan: Patient-relevant outcomes in comprehensive cancer centers vs noncomprehensive cancer centers
Blog
Nov 22, 2024, 10:07
How is your country doing on cancer screening? New tool to monitor cancer screening policies by ECO
Blog
Nov 22, 2024, 10:02
Key updates on cervical cancer screening - ACS National Roundtable on Cervical Cancer
Blog
Nov 22, 2024, 09:56
Miriam Mutebi about Breast Cancer Risk Factors
Oncolibrary
Nov 22, 2024, 08:13
Side Effects of Radiotherapy: Risks and What to Know
Insight
Nov 21, 2024, 21:47
Ilya Vasilchenko: Optimizing Data Handling for Peptide Drug Discovery
Blog
Nov 21, 2024, 21:40
Gilly Mathieson: Celebrating the resilience and power of advocacy at ENTERO24
Blog
Nov 21, 2024, 21:36
Amol Akhade: Metastatic colorectal cancer - third line and beyond
Blog
Nov 21, 2024, 21:31
Enrique Grande: Lucky to participate in the Annual Congress of the Spanish Group of Neuroendocrine Tumors
Blog
Nov 21, 2024, 21:27
Amol Akhade: Current treatment and data of Esophageal cancer
Blog
Nov 21, 2024, 21:23
Call for abstracts for ESMO Sarcoma and Rare Cancers 2025
Blog
Nov 21, 2024, 21:17
Angela Mastronuzzi: 30 years of Peter Pan ODV